Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Grabowski
D
D
Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195, USA.
Ganapathi
R
R
D000677:Amsacrine / Q000008:administration & dosage; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005047:Etoposide / Q000008:administration & dosage; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D008942:Mitoxantrone / Q000008:administration & dosage; D059004:Topoisomerase I Inhibitors; D019772:Topotecan
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D000677:Amsacrine; D005047:Etoposide; D019772:Topotecan; D008942:Mitoxantrone; D002166:Camptothecin